End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.69 USD | -0.89% | +14.00% | +166.25% |
May. 16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
May. 10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
Financials (USD)
Sales 2024 * | 1.82M | Sales 2025 * | 1.98M | Capitalization | 752M |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | -88M | EV / Sales 2024 * | 241 x |
Net cash position 2024 * | 314M | Net cash position 2025 * | 518M | EV / Sales 2025 * | 118 x |
P/E ratio 2024 * |
-11.7
x | P/E ratio 2025 * |
-9.85
x | Employees | 53 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.16% |
1 day | -0.89% | ||
1 week | +14.00% | ||
Current month | +29.70% | ||
1 month | +18.64% | ||
3 months | +14.90% | ||
6 months | +143.96% | ||
Current year | +166.25% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 25.63 | -2.36% | 88,687 |
24-05-16 | 26.25 | -5.20% | 90,942 |
24-05-15 | 27.69 | -0.89% | 114,608 |
24-05-14 | 27.94 | +7.42% | 96,629 |
24-05-13 | 26.01 | +7.08% | 103,074 |
End-of-day quote Nasdaq, May 14, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+166.25% | 752M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- DNTH Stock